Insmed (INSM), which announced that its Phase 2b CEDAR study did not meet primary endpoint, is set to resume trading at 4:30pm ET, with quotation scheduled to resume at 4:25pm ET, according to Nasdaq.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: